SA
Log In
TNDM
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
37 analysts·High coverage
66
Score
24 Buy (65%)13 Hold (35%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2465%
Hold
1335%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$21.00
+16.5%
Consensus
$28.00
+55.3%
Bull
$56.00
+210.6%
12-Month Target Range37 analysts
$21.00$28.00$56.00
Current $18.03Consensus
Current Price
$18.03
Upside to Consensus
$9.97

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+12.06%
EPS—
FY2028
Rev+13.69%
EPS+2270.57%
FY2029
Rev+14.34%
EPS+102.15%

Earnings Surprises

Recent Analyst Actions

Apr 24, 2026Redburn Partners
Tandem Diabetes price target raised to $45 from $36 at Rothschild & Co Redburn
Target:$45.00
+117.6%from $20.68
Feb 23, 2026Truist Financial
Tandem Diabetes price target raised to $27 from $24 at Truist
Target:$27.00
+9.9%from $24.57
Feb 23, 2026Lake Street
Tandem Diabetes upgraded to Buy from Hold at Lake Street
Target:$50.00
+103.5%from $24.57
Feb 23, 2026Goldman Sachs
Tandem Diabetes price target raised to $28 from $25 at Goldman Sachs
Target:$28.00
+14.0%from $24.57
Feb 23, 2026Barclays
Tandem Diabetes price target raised to $56 from $55 at Barclays
Target:$56.00
+127.9%from $24.57
Feb 20, 2026Mizuho Securities
Tandem Diabetes price target raised to $22 from $21 at Mizuho
Target:$22.00
+18.8%from $18.52
Feb 20, 2026Stifel Nicolaus
Tandem Diabetes price target raised to $22 from $20 at Stifel
Target:$22.00
+18.8%from $18.52
Feb 20, 2026UBS
Tandem Diabetes price target raised to $22 from $17 at UBS
Target:$22.00
+18.8%from $18.52
Feb 20, 2026Piper Sandler
Tandem Diabetes price target raised to $21 from $14 at Piper Sandler
Target:$21.00
+13.4%from $18.52
Feb 4, 2026Stifel Nicolaus
Tandem Diabetes price target raised to $20 from $16 at Stifel
Target:$20.00
+4.7%from $19.11
Jan 9, 2026Goldman Sachs
Tandem Diabetes price target raised to $25 from $16 at Goldman Sachs
Target:$25.00
+11.1%from $22.50
Dec 18, 2025Truist Financial
Tandem Diabetes price target raised to $24 from $17 at Truist
Target:$24.00
+8.0%from $22.22
Dec 17, 2025RBC Capital
Tandem Diabetes price target raised to $30 from $25 at RBC Capital
Target:$30.00
+31.5%from $22.81
Dec 17, 2025Canaccord Genuity
Tandem Diabetes price target raised to $35 from $24 at Canaccord
Target:$35.00
+54.9%from $22.60
Dec 17, 2025Mizuho Securities
Tandem Diabetes price target raised to $21 from $18 at Mizuho
Target:$21.00
-7.1%from $22.60
Dec 16, 2025Robert W. Baird
Tandem Diabetes upgraded to Outperform from Neutral at Baird
Target:$30.00
+35.6%from $22.12
Dec 2, 2025Morgan Stanley
Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley
Target:$23.00
+12.1%from $20.51
Oct 15, 2025Truist Financial
Tandem Diabetes price target raised to $16 from $14 at Truist
Target:$16.00
+5.9%from $15.11
Sep 8, 2025Oppenheimer
Tandem Diabetes assumed with an Outperform at Oppenheimer
Target:$22.00
+76.0%from $12.50
Aug 7, 2025Canaccord Genuity
Tandem Diabetes price target lowered to $24 from $59 at Canaccord
Target:$24.00
+114.4%from $11.20
Aug 7, 2025Piper Sandler
Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler
Target:$14.00
-2.7%from $14.39
Mar 5, 2025Morgan Stanley
Tandem Diabetes downgraded to Equal Weight from Overweight at Morgan Stanley
Target:$22.00
+15.1%from $19.11
Feb 28, 2025Bernstein
Tandem Diabetes downgraded to Market Perform from Outperform at Bernstein
Target:$25.00
+12.9%from $22.14
Feb 28, 2025Barclays
Tandem Diabetes price target lowered to $53 from $60 at Barclays
Target:$53.00
+139.4%from $22.14
Jan 8, 2025Bernstein
Tandem Diabetes price target raised to $44 from $42 at Bernstein
Target:$44.00
+17.4%from $37.49

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance